Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYCAN: Hyperthermia in Anal Carcinoma
NCT02369939Phase 3Unknown
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Dec 2014
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anal squamous cell carcinoma (SCCA), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Complete Remission at 12 weeks. Status: unknown.
02
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT02369939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369939.